Kabir B Nigam (Kabir Nigam)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 6

Top Topics

Major Depressive Disorder

Papillary Thyroid

Machine Learning

Mesenchymal Stem Cells

Top Venues

Journal of psychopharmacology (Oxford, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Kabir B Nigam, Franklin King, Fernando Espi Forcen
Ketamine for refractory depression: Save the best for last? Journal of psychopharmacology (Oxford, England) (2024)
Yvan Beaussant, Elise C Tarbi, Kabir B Nigam, Skye Miner, Zachary Sager, Justin J Sanders, Michael Ljuslin, Benjamin Guérin, Paul Thambi, James A Tulsky, Manish Agrawal
Acceptability of psilocybin-assisted group therapy in patients with cancer and major depressive disorder: Qualitative analysis. Cancer 130 (7) (2023)
Yvan Beaussant, Elise C Tarbi, Kabir B Nigam, Skye Miner, Zachary Sager, Justin J Sanders, Michael Ljuslin, Benjamin Guérin, Paul Thambi, James A Tulsky, Manish Agrawal
Acceptability of psilocybin-assisted group therapy in patients with cancer and major depressive disorder: Qualitative analysis. Cancer (2023)
Yvan Beaussant, Elise C Tarbi, Kabir B Nigam, Skye Miner, Zachary Sager, Justin J Sanders, Michael Ljuslin, Benjamin Guérin, Paul Thambi, James A Tulsky, Manish Agrawal
Acceptability of psilocybin-assisted group therapy in patients with cancer and major depressive disorder: Qualitative analysis. Cancer 130 (7) (2023)
Yvan Beaussant, Elise C Tarbi, Kabir B Nigam, Skye Miner, Zachary Sager, Justin J Sanders, Michael Ljuslin, Benjamin Guérin, Paul Thambi, James A Tulsky, Manish Agrawal
Acceptability of psilocybin-assisted group therapy in patients with cancer and major depressive disorder: Qualitative analysis. Cancer 130 (7) (2023)
Anisha K Nigam, Anupam Anand Ojha, Julia G Li, Da Shi, Vibha Bhatnagar, Kabir B Nigam, Ruben Abagyan, Sanjay K Nigam
Molecular Properties of Drugs Handled by Kidney OATs and Liver OATPs Revealed by Chemoinformatics and Machine Learning: Implications for Kidney and Liver Disease. Pharmaceutics 13 (10) (2021)